Impact of SARS-CoV-2 antibodies at delivery in women, partners and newborns
Rattachement africain : dk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Only few studies have focused on serological testing for SARS-CoV-2 in pregnant women and no previous study has investigated the frequency in partners. The aim was to investigate the frequency and impact of SARS-CoV-2 in parturient women, their partners and newborns. Methods From April 4 th to July 3 rd , 2020, all parturient women, their partners and newborns were invited to participate in the study. Participating women and partners had a pharyngeal swab and a blood sample taken at admission and immediately after delivery a blood sample was drawn from the umbilical cord. The swabs were analyzed for SARS-CoV-2 RNA by PCR and the blood samples were analyzed for SARS-CoV-2 antibodies. Full medical history, obstetric- and neonatal information were available. Results A total of 1,361 parturient women, 1,236 partners and 1,342 newborns participated in the study. No associations between previous COVID-19 disease and obstetric- or neonatal complications were found. The adjusted serological prevalence was 2.9% in women and 3.8% in partners. The frequency of blood type A was significantly higher in women with antibodies compared to women without antibodies. 17 newborns had SARS-CoV-2 IgG antibodies, and none had IgM antibodies. Full serological data from 1,052 families showed an absolute risk of infection of 0.37 if the partner had antibodies. Only 55% of individuals with antibodies reported symptoms. Conclusion This large prospective cohort study reports no association between COVID-19 and obstetric- or neonatal complications. The family pattern showed a substantial increase in absolute risk for women living with a partner with antibodies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Impact of SARS-CoV-2 antibodies at delivery in women, partners and newborns
- Date Crossref
- 15/09/2020
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hvidovre Hospital pays non établi dans la noticeÉtablissement de santé
-
Copenhagen University Hospital Department of Obstetrics and Gynaecology pays non établi dans la noticeÉtablissement de santé
-
University of Copenhagen Novo Nordisk Foundation Center for Protein Research pays non établi dans la noticeUniversité ou école supérieure
-
Statistics Denmark pays non établi dans la noticeOrganisme public
-
Novo Nordisk Foundation pays non établi dans la noticeStructure de recherche
-
Rigshospitalet pays non établi dans la noticeÉtablissement de santé
-
Methods and Analysis pays non établi dans la noticeInstitution
-
Faculty of Health and Medical Sciences Department of Clinical Medicine pays non établi dans la noticeUniversité ou école supérieure
Hvidovre Hospital, Department of Obstetrics and Gynaecology — Copenhagen University Hospital et Novo Nordisk Foundation Center for Protein Research — University of Copenhagen, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.